BioNTech's Rough Week: A Sector Shock, a Founder's Sell-Down, and a Pipeline That Says Otherwise

BioNTech slid 6.2% for the week as Novartis' Pelacarsen miss hit biotech sentiment, even as its oncology pipeline and BNT327 data drew investor attention.

BioNTech closed Friday at EUR 83.65, up 0.7% on the day — a modest bounce that did little to soften a bruising stretch in which the stock shed roughly 6.2% over the week and dipped as low as EUR 82.60 at one point. The retreat looks especially stark next to January's 52-week high of EUR 105.80, a level the shares now sit about 21% below. Yet the forces behind the slide have less to do with BioNTech's own news flow than with a shock that landed elsewhere in biotech.

A failed endpoint in Zurich ripples through the whole sector

The trigger came from Novartis, which disclosed in early September that its cholesterol drug Pelacarsen succeeded in lowering Lp(a) levels but missed the primary composite endpoint of heart attacks, strokes, and cardiovascular deaths. The market's answer was swift and severe. Ionis Pharmaceuticals, which originally discovered and developed the compound before licensing it to Novartis, gave up around 10% on September 8. Amgen, whose rival olpasiran program now faces closer scrutiny, dropped USD 44.06 to USD 393.17 — its worst trading session since October 2000. Novartis itself lost roughly 3% in Zurich.

BioNTech has no exposure to lipoprotein(a) therapies, yet it was dragged down by the broad nervousness that swept the sector. The episode illustrates how tightly interwoven biotech sentiment has become: a single missed endpoint in a cardiovascular drug can spark selling pressure in names with no connection to the underlying science.

The oncology story keeps building, even as the tape says otherwise

What makes the weakness harder to square is that BioNTech's own fundamentals have been anything but barren. Investor forums are buzzing about the BNT327 and BNT324 combination in small-cell lung cancer, where response rates are said to run above 70% in some treatment lines and beyond 90% in others. A Phase 3 trial of BNT327 against Keytruda in non-small-cell lung cancer is under way, and BNT323 could secure approval in China by 2026.

The caveats deserve a hearing: mature overall survival data are still missing, and the commercial horizon for these programs stretches into the 2030s. Anyone hunting for a near-term catalyst is likely to come away frustrated. That distinction matters, though — BioNTech's oncology assets rest on encouraging early data and a mid-term thesis, not on a binary, all-or-nothing readout like Novartis' Pelacarsen.

Valuation leans on pipeline expectations, not near-term earnings

With a market capitalization of roughly EUR 20.85 billion and a negative P/E of -18.00, BioNTech's valuation is driven overwhelmingly by expectations for its oncology pipeline. The shares have recovered 22% from their March low, a swing that underscores how sharply investor sentiment tracks clinical progress. On balance, the recent softness reflects sector-wide jitters more than company-specific risk — the collateral damage from Novartis has clouded the entire biotech segment, while BioNTech's own data, caveats included, argue more for the company than against it. Judging BioNTech purely on last week's price action risks missing the substance underneath.

Insider selling continues, with execution prices sliding

Meanwhile, CEO Ugur Sahin has kept trimming his stake. Over several trading days and through multiple Rule 10b5-1 arrangements, he disposed of more than 125,000 shares in total: 31,500 at USD 103.52 on September 4, 37,000 at USD 99.20 on September 8, 36,000 at USD 97.78 on September 9, and 20,500 at USD 96.31 on September 10.

The declining execution prices track the stock's broader weakness over that window. Such transactions follow pre-set trading plans and say nothing directly about business conditions, but the falling prints drew close attention from investors nonetheless. Following the September 10 sale, Sahin still holds 688,209 shares directly and 39,218,111 shares indirectly through Medine GmbH — a stake that underscores his long-term commitment despite the ongoing partial sales.

Institutional investors have been moving too. Fund manager Carmignac Gestion cut its BioNTech position by 29.1% in the second quarter, selling 32,836 shares. Its remaining 79,875 shares are valued at about USD 7.45 million. Portfolio adjustments of this kind are not alarming on their own, but they fit a picture of growing caution among part of the institutional base.

A backdrop of setbacks meets a founder's scheduled exits

The insider sales arrive during a stretch in which BioNTech has already contended with a lowered revenue forecast, the discontinuation of a cancer study, and a disappointing quarterly report — issues that had weighed on the shares in the weeks before. That Sahin sold across several consecutive transactions at declining prices may be read by investors as another signal of uncertainty around the company's near-term trajectory, even though the sales unfold under long-term trading plans and his stake via Medine GmbH remains substantial.